Insider Stock Trading History of Sieczkarek Mark M


The following table details the trading activities (stock purchases, stock sales, and stock option exercises) reported to the Securities and Exchange Commission (SEC) by insider Sieczkarek Mark M since year 2005. The trader's CIK number is 1188738. At the time of this reporting, Sieczkarek Mark M is the Director of Novabay Pharmaceuticals, Inc. . (stock ticker symbol NBY). See this page for all insider trading activities at Novabay Pharmaceuticals, Inc. .

Note that in the past SIECZKAREK MARK M also reported insider trading activities as an insider of the following companies:
Stock purchases, sales, and option exercises reported by insider Sieczkarek Mark M since 2005.
  Trade Date   Symbol Company Name (Issuer) Trade Type     Shares       Price ($)   Value ($)
2015-03-03 NBY Novabay Pharmaceuticals, Inc. Buy 166,666 .60 99,999
2014-06-04 NBY Novabay Pharmaceuticals, Inc. Buy 4,800 .89 4,272
2014-05-19 NBY Novabay Pharmaceuticals, Inc. Buy 25,000 .88 22,000
2013-05-06 SLTM Thermage Inc Buy 150,000 1.74 261,000
2010-02-19 CPTS Conceptus Inc Sale 69,789 22.00 1,535,358
2010-01-20 CPTS Conceptus Inc Option Ex 98,311 9.95 978,194
2010-01-20 CPTS Conceptus Inc Sale 98,311 20.00 1,966,220
2009-10-22 CPTS Conceptus Inc Option Ex 1,689 9.95 16,805
2009-10-22 CPTS Conceptus Inc Sale 1,689 20.00 33,780
2009-09-23 CPTS Conceptus Inc Option Ex 95,387 9.95 949,100
2009-09-23 CPTS Conceptus Inc Sale 95,387 19.00 1,812,353
2009-09-09 CPTS Conceptus Inc Option Ex 4,613 9.95 45,899
2009-09-09 CPTS Conceptus Inc Sale 4,613 19.00 87,647
2007-12-13 CPTS Conceptus Inc Sale 31,317 19.55 612,247
2005-08-09 CPTS Conceptus Inc Buy 10,000 8.10 81,000
2005-08-09 CPTS Conceptus Inc Buy 10,000 8.00 80,000

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Sieczkarek Mark M (Director of Novabay Pharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.